JP2010536745A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536745A5
JP2010536745A5 JP2010520684A JP2010520684A JP2010536745A5 JP 2010536745 A5 JP2010536745 A5 JP 2010536745A5 JP 2010520684 A JP2010520684 A JP 2010520684A JP 2010520684 A JP2010520684 A JP 2010520684A JP 2010536745 A5 JP2010536745 A5 JP 2010536745A5
Authority
JP
Japan
Prior art keywords
fibronectin
erythropoietin
dose
tissue
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010520684A
Other languages
English (en)
Japanese (ja)
Other versions
JP5869219B2 (ja
JP2010536745A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2008/001119 external-priority patent/WO2009022338A2/en
Publication of JP2010536745A publication Critical patent/JP2010536745A/ja
Publication of JP2010536745A5 publication Critical patent/JP2010536745A5/ja
Application granted granted Critical
Publication of JP5869219B2 publication Critical patent/JP5869219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010520684A 2007-08-16 2008-08-13 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物 Active JP5869219B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US93549707P 2007-08-16 2007-08-16
US60/935,497 2007-08-16
US6431108P 2008-02-27 2008-02-27
US61/064,311 2008-02-27
PCT/IL2008/001119 WO2009022338A2 (en) 2007-08-16 2008-08-13 Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications

Publications (3)

Publication Number Publication Date
JP2010536745A JP2010536745A (ja) 2010-12-02
JP2010536745A5 true JP2010536745A5 (cg-RX-API-DMAC7.html) 2011-09-29
JP5869219B2 JP5869219B2 (ja) 2016-02-24

Family

ID=40351263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010520684A Active JP5869219B2 (ja) 2007-08-16 2008-08-13 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物

Country Status (5)

Country Link
US (7) US20110123481A1 (cg-RX-API-DMAC7.html)
EP (1) EP2192907B1 (cg-RX-API-DMAC7.html)
JP (1) JP5869219B2 (cg-RX-API-DMAC7.html)
PL (1) PL2192907T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009022338A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5564735B2 (ja) * 2009-07-31 2014-08-06 国立大学法人 熊本大学 アクアポリン3の発現調節剤
WO2011104707A1 (en) * 2010-02-23 2011-09-01 Remedor Biomed Ltd. Methods and compositions for enhancing fat graft survival
KR20150133222A (ko) * 2013-03-13 2015-11-27 스테메트릭스, 인코포레이티드. 피부 조성물 및 피부 조성물의 용도
CN105188781A (zh) * 2013-05-07 2015-12-23 国立大学法人东京医科齿科大学 用于制备微粒脱细胞组织的方法
CN107427559A (zh) * 2015-09-04 2017-12-01 赛巴纳医药有限公司 局部用红细胞生成素制剂和用其提高伤口愈合的方法及其美容用途
WO2017104725A1 (ja) * 2015-12-16 2017-06-22 第一三共株式会社 創傷治療剤
CN109071482A (zh) 2016-01-15 2018-12-21 汉堡大学 携有o-鼠李糖基残基的类黄酮型化合物
EP3402893A1 (en) 2016-01-15 2018-11-21 Universität Hamburg Methods for the production of rhamnosylated flavonoids
JP2019522652A (ja) * 2016-06-21 2019-08-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Braf阻害剤を用いる創傷治癒
CA3042295A1 (en) * 2016-11-10 2018-05-17 Asc Regenity Ltd. Cosmetic formulations for topical applications containing erythropoietin-derived molecules
JP7605576B2 (ja) * 2018-07-25 2024-12-24 ポーラ化成工業株式会社 皮膚老化改善剤のスクリーニング方法
JP2020070270A (ja) * 2018-11-01 2020-05-07 御木本製薬株式会社 フィブロネクチン遺伝子発現促進剤
CN116531306A (zh) * 2023-02-27 2023-08-04 珠海盈盛联科生物科技有限公司 含重组人纤连蛋白具有修复功效组合物、制备方法及应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
DE2437090A1 (de) 1974-08-01 1976-02-19 Hoechst Ag Reinigungsmittel
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5124155A (en) 1988-06-21 1992-06-23 Chiron Ophthalmics, Inc. Fibronectin wound-healing dressings
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5264214A (en) 1988-11-21 1993-11-23 Collagen Corporation Composition for bone repair
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073372A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5564345A (en) * 1993-05-11 1996-10-15 Park Ohio Industries Inc. Stackable table, table assembly, and tray and table combination
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
GB9315810D0 (en) * 1993-07-30 1993-09-15 Univ London Stabilised materials
US7112320B1 (en) * 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
US6458889B1 (en) * 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US6007802A (en) 1996-03-27 1999-12-28 The Procter & Gamble Co. Conditioning shampoo composition
KR20000076136A (ko) * 1997-03-11 2000-12-26 스즈키 츠네시 피부 상태 개선제의 평가 방법 및 피부 외용제의 제조 방법
CA2232855C (en) * 1997-04-10 2007-10-09 Roche Consumer Health (Worldwide) Sa Pharmaceutical formulation
NZ505324A (en) * 1997-12-22 2002-11-26 Human Genome Sciences Inc Liquid and lyophilised KGF-2 polypeptide formulations used to accelerate soft tissue growth or regeneration
US6194378B1 (en) * 1998-02-18 2001-02-27 The Research Foundation Of State University Of New York Fibronectin peptides-based extracellular matrix for wound healing
GB9804720D0 (en) 1998-03-05 1998-04-29 Unilever Plc Shampoo compositions
WO2000004941A1 (en) 1998-07-24 2000-02-03 Pharmacal Biotechnologies, Inc. Osseous tissue reconstruction system and method
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US6960173B2 (en) 2001-01-30 2005-11-01 Eilaz Babaev Ultrasound wound treatment method and device using standing waves
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
US6913762B2 (en) 2001-04-25 2005-07-05 Mayo Foundation For Medical Education And Research Stent having non-woven framework containing cells
US20030147825A1 (en) * 2001-06-08 2003-08-07 Chiarelli Joseph A. Personal care compostions containing inverse emulsion polymers
US20030068297A1 (en) * 2001-08-18 2003-04-10 Deepak Jain Composition and methods for skin rejuvenation and repair
US20040265268A1 (en) 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
AU2003219916A1 (en) 2002-02-22 2003-09-09 University Of Washington Bioengineered tissue substitutes
AU2003242246A1 (en) 2002-06-06 2003-12-22 Chugai Seiyaku Kabushiki Kaisha Remedy for bone mtabolic diseases
WO2004001023A2 (de) 2002-06-20 2003-12-31 Bionethos Holding Gmbh Verfahren und vorrichtung zur vermehrung und differenzierung von zellen in anwesenheit von wachstumsfaktoren und einer biologischen matrix oder trägerstruktur
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE10303584A1 (de) 2003-01-30 2004-08-12 Stauss, Robert, Dr. Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten
NZ542501A (en) * 2003-02-24 2009-09-25 Marinepolymer Tech Inc Compositions comprising chitin or chitosan and use thereof
US7459152B2 (en) 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
WO2005037304A1 (en) * 2003-10-17 2005-04-28 Crucell Holland B.V. Treatment and prevention of decubitus
EP1691852A2 (en) 2003-11-10 2006-08-23 Angiotech International AG Medical implants and fibrosis-inducing agents
EP1550715A1 (de) 2003-12-30 2005-07-06 Bionethos Holding Gmbh Verfahren zur Regenation von Gewebe
ES2606068T3 (es) 2003-12-30 2017-03-17 Augustinus Bader Eritropoyetina para uso en el tratamiento de heridas o el trasplante de células
WO2005070451A1 (en) * 2004-01-22 2005-08-04 Zafena Aktiebolag Pharmaceutical composition comprising non-glycosylated erythropoietin
DE102004004509B4 (de) 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
EP1865982A1 (en) * 2005-04-06 2007-12-19 Bioartificial Gel Technologies Inc. Hydrogel composition for modulation of topical inflammatory response
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
CA2608021A1 (en) * 2005-05-10 2006-11-16 Dermipsor Ltd. Compositions and methods for skin care
US7312198B2 (en) * 2005-07-12 2007-12-25 Essential Skincare, Llc Protein compositions for promoting wound healing and skin regeneration
EP1942928A2 (en) 2005-10-31 2008-07-16 Essential Skincare, LLC Protein composition for promoting wound healing and skin regeneration
US8361781B2 (en) 2006-01-24 2013-01-29 Brown University Cell aggregation and encapsulation device and method
CA2651856C (en) * 2006-05-11 2015-09-29 Regenics As Administration of cells and cellular extracts for rejuvenation
KR20140032505A (ko) * 2006-11-09 2014-03-14 알콘 리서치, 리미티드 약물 전달용 수불용성 폴리머 매트릭스
US7717855B2 (en) * 2006-12-06 2010-05-18 The Hospital For Sick Children System for performing remote ischemic preconditioning
US20090068255A1 (en) * 2007-04-30 2009-03-12 Betty Yu Use of matrix metalloproteinase inhibitors in skin care
CA2691024A1 (en) 2007-06-19 2008-12-24 Baxter Healthcare S.A. Fibrin gel for controlled release of pdgf and uses thereof
EP2018835B1 (de) * 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
US20090045968A1 (en) 2007-08-16 2009-02-19 Optimal Innovations Inc. Utility Outlets Capable of Presenting Images
RU2465003C2 (ru) 2007-12-28 2012-10-27 Херойс Кульцер Гмбх Местное нанесение и препараты эритропоэтина для заживления кожных ран
US20100310626A1 (en) 2008-01-24 2010-12-09 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for bone regeneration

Similar Documents

Publication Publication Date Title
JP2010536745A5 (cg-RX-API-DMAC7.html)
ES2720271T3 (es) Composiciones de gel tópico que contienen un polímero de policaprolactona y métodos para mejorar la aplicación tópica de un agente beneficioso
CN100415246C (zh) 二氧化碳外用剂调制用组合物
CN102949709B (zh) 一种治疗糖尿病足的外用凝胶剂及制备和应用
JP5654987B2 (ja) 日光角化症の処置のための局所用組成物
JP6989157B2 (ja) 電気化学ガス状伝達物質生成組成物及びその使用方法ならびにそれを組み込んだ被覆材及び治療システム
US20170239359A1 (en) Anhydrous hydrogel composition and delivery system
UA89500C2 (uk) Органогель для терапевтичного застосування
RU2012133969A (ru) Локальные трансдермальные композиции дексмедетомидина и способы их применения
CA2891075A1 (en) Dermal compositions containing unnatural hygroscopic amino acids
JP2002526407A5 (cg-RX-API-DMAC7.html)
CN105056286B (zh) 液体创可贴及其制备方法
WO2002094256A1 (en) Lysine and/or analogues and/or polymers thereof for promoting wound healing and angiogenesis
WO2014210308A1 (en) Method of reducing scarring
CN105209051A (zh) 痤疮溶液
CN103143052A (zh) 医用胶原敷料及其制备方法和用途
HUP0302038A2 (hu) Biguanidszármazékok alkalmazása hegesedést elżsegítż gyógyszerek elżállítására
RU2015148636A (ru) Модуляция активности гепарин-связывающего эпидермального фактора роста для заживления барабанной перепонки
RU2010138947A (ru) Состав для топического применения, содержащий микросферы адапалена и клиндамицин
RU2159113C1 (ru) Средство, обладающее противовоспалительным, антисептическим и регенераторным действием
CN1990045B (zh) 一种新型高效烧烫伤类贴剂及其制备方法
CN104027346B (zh) 一种治疗伤口溃烂的药物组合物及其制备方法
EP2663335A1 (en) A composition for the regeneration of atrophic tissues
CN106880765A (zh) 一种外伤动物模型的构建及促进伤口愈合的方法
CN1938009A (zh) 包含用齐墩果提取物和/或紫罗烯聚合物稳定的维生素和/或其衍生物的组合物